Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Abbreviations: CD, cluster of differentiation; CeD, celiac disease; CTLA4, cytotoxic T‐lymphocyte‐associated protein 4; GD, Graves' disease; HT, Hashimoto's thyroiditis; IL2‐Rα, interleukin‐2 receptor α; PAS, polyglandular autoimmune syndrome; PTPN22, protein tyrosine phosphatase non‐receptor type 22; T1D, type 1 diabetes; TNF, tumour necrosis factor; VDR, vitamin D receptor.

Source: Mechanisms Linking Type 1 Diabetes to Other Autoimmune Diseases. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Publisher article type: review-article

Source: Publisher publication metadata.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Type 1 Diabetes and Other Autoimmune Diseases: Epidemiology, Pathophysiology and Screening

Review / evidence synthesis · Endocrinology, Diabetes & Metabolism · 2025

Original publication title

Type 1 Diabetes and Other Autoimmune Diseases: Epidemiology, Pathophysiology and Screening

George J. Kahaly; Thomas Forst; Monika Kellerer; Stefanie Lanzinger; René D. Rötzer; Matthias Schott; Petra‐Maria Schumm‐Draeger

© 2025 The Author(s). Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Accordingly, screening for T1D‐associated autoantibodies in individuals with a personal or family history of AIDs, and vice versa, should be implemented in clinical practice.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The interplay between type 1 diabetes (T1D) and concomitant autoimmune diseases (AID) is both clinically and scientifically relevant. In this review, we delineate the epidemiological, pathophysiological and practical aspects underlying polyautoimmunity with a focus on T1D.

Source: Introduction

Abstract: What methods does the paper describe?

A comprehensive review of literature on T1D and associated AID was conducted, with the aim of drawing informed conclusions relevant to clinical practice. It draws on a targeted PubMed search conducted March: May 2025, emphasising recent peer‐reviewed articles in English.

Source: Method

Abstract: Results

Epidemiological data consistently indicate that individuals with T1D exhibit a significantly increased prevalence of additional AID. Familial aggregation of discordant AID and the concept of polyglandular autoimmune syndromes (PAS) or autoimmune polyendocrinopathy highlight that multiple AID can cluster and occur in a sequential and overlapping fashion, with T1D frequently acting as either an early or a subsequent manifestation. Thereby, genetic susceptibility, environmental triggers and epigenetic factors are pivotal in the initiation and progression of autoimmunity. Clinically, the coexistence of T1D with other AID poses significant challenges in disease management, often necessitating adjustments in therapeutic regimens and careful monitoring to mitigate complications.

Early detection via stratified autoantibody testing is important for timely intervention and improved long‐term outcomes.

Source: Results

Abstract: Conclusions

Accordingly, screening for T1D‐associated autoantibodies in individuals with a personal or family history of AIDs, and vice versa, should be implemented in clinical practice.

Source: Conclusions
Authors’ abstract

ABSTRACT

Introduction

The interplay between type 1 diabetes (T1D) and concomitant autoimmune diseases (AID) is both clinically and scientifically relevant. In this review, we delineate the epidemiological, pathophysiological and practical aspects underlying polyautoimmunity with a focus on T1D.

Method

A comprehensive review of literature on T1D and associated AID was conducted, with the aim of drawing informed conclusions relevant to clinical practice. It draws on a targeted PubMed search conducted March: May 2025, emphasising recent peer‐reviewed articles in English.

Results

Epidemiological data consistently indicate that individuals with T1D exhibit a significantly increased prevalence of additional AID. Familial aggregation of discordant AID and the concept of polyglandular autoimmune syndromes (PAS) or autoimmune polyendocrinopathy highlight that multiple AID can cluster and occur in a sequential and overlapping fashion, with T1D frequently acting as either an early or a subsequent manifestation. Thereby, genetic susceptibility, environmental triggers and epigenetic factors are pivotal in the initiation and progression of autoimmunity. Clinically, the coexistence of T1D with other AID poses significant challenges in disease management, often necessitating adjustments in therapeutic regimens and careful monitoring to mitigate complications.

Early detection via stratified autoantibody testing is important for timely intervention and improved long‐term outcomes.

Conclusions

Accordingly, screening for T1D‐associated autoantibodies in individuals with a personal or family history of AIDs, and vice versa, should be implemented in clinical practice.

Publication and source details

Original title: Type 1 Diabetes and Other Autoimmune Diseases: Epidemiology, Pathophysiology and Screening

George J. Kahaly; Thomas Forst; Monika Kellerer; Stefanie Lanzinger; René D. Rötzer; Matthias Schott; Petra‐Maria Schumm‐Draeger

Endocrinology, Diabetes & Metabolism · 2025

* Correspondence:
George J. Kahaly (george.kahaly@unimedizin-mainz.de)
© 2025 The Author(s). Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Sanofi‐Aventis Deutschland GmbH Sciarc GmbH, Baierbrunn, Germany

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:52:44.486342+00:00

DOI: 10.1002/edm2.70119 · PMC12664531